Ami V Desai
Children's Oncology Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ami V Desai as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:38 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04385277 · Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)Children's Oncology Group · active not recruiting · Ganglioneuroblastoma, Nodular, Neuroblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- COG NCTN Network Group Operations CenterU10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2014 to 2026Named on NCT04385277
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:38 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- 159 citationsRCR 5.5
- Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.Nat Med · 2023122 citationsRCR 11.1
- Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).Neuro Oncol · 2022117 citationsRCR 8.2
- Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.Antimicrob Agents Chemother · 2017103 citationsRCR 5.9
- Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.Clin Cancer Res · 202139 citationsRCR 1.8
- Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.Cancer Chemother Pharmacol · 201437 citationsRCR 1.2
- Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.Eur J Clin Pharmacol · 201737 citationsRCR 1.9
- Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.Antimicrob Agents Chemother · 201732 citationsRCR 1.8
- Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions.Eur J Cancer · 202521 citationsRCR 4.6
- 16 citationsRCR 3.9